key: cord-0077504-g5dc7oah
authors: Khuntia, Bharat Krushna; Agarwal, Aman; Sharma, Gautam
title: Letter to Editor on "A Randomized, Controlled, Blinded, Parallel-Group, Clinical Trial to study the role of Ayurcov (AyurCoro3), a one-day regimen as an adjuvant therapy for COVID-19 disease management, at dedicated Covid Hospital (DCH) in India"
date: 2022-04-26
journal: Complement Ther Med
DOI: 10.1016/j.ctim.2022.102838
sha: 9504a947cdfa2f286e96514e7f9e1d1db9bb8e40
doc_id: 77504
cord_uid: g5dc7oah

nan

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. The author has highlighted the need to integrate Ayurveda medicines and therapies for effective COVID-19 management in the introduction. But this single-day interventional regimen (three times oral drugs and two times gargle) is neither supported by the classical Ayurvedic textual recommendations nor adequately supported by scientific evidence. Therefore, it seems unconvincing that a single day therapy of "Ayurcov" can affect the outcome in the COVID-19 patients.

We also observed that the formula used for sample size calculation in the manuscript is not appropriate for randomized controlled trials. Because of this, it is possible that primary outcome measures were not statistically significant.

Reporting of the primary outcome based on the presence of COVID-19 symptoms (Table no. 3) possibly fails to assess the small changes in the level of the improvement. Spinner et al. 2 , for example, have used an ordinal seven-point scale to evaluate the efficacy of COVID-19 therapeutics on clinical status. Also, while comparing the number of patients with presenting symptoms in both groups, the authors have reported statistical significance by binary logistic regression. However, binary logistic regression is not an appropriate statistical tool to obtain the effect size in randomized controlled trials as it may overestimate the effect size. 3 It would be prudent to use the z test for two independent proportions to determine statistical significance.

Hence, based on the above comments, we believe the results of the current study should be interpreted cautiously.

Declaration of Competing Interest: None Source of Funding: None

Clinical Trial to study the role of Ayurcov (AyurCoro3), one day regimen as an adjuvant therapy for COVID-19 disease management, at dedicated Covid Hospital (DCH) in India

Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19

Odds ratio vs risk ratio in randomized controlled trials